Medical Device News Magazine

Non-Pharmaceutical Clinical Trial Starts Using Photobiomodulation to Treat Intubated COVID-19 Patients

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

May 27, 2020

Non-Pharmaceutical clinical trial started by researchers in Brazil using Multi Radiance Medical super pulsed laser therapy technology as an adjunctive means to improve critical care for COVID-19 patients is underway.

Approved by the Ministry of Health in Brazil, a group of international physicians and scientists are in the early stages of data collection utilizing Multi Radiance Medical’s handheld super pulsed laser therapy devices to improve the condition of patients.

The study, the first of its kind to utilize light therapy for COVID-19 patient recovery, will evaluate the respiratory muscle function and levels of inflammation during intubation. There is a profound effect seen following a brief exposure to multi-wavelength light on muscle fatigue.

Coordinated by Drs. Fabio Francio, Ernesto Leal-Junior, and Thiago DeMarchi, the trial aims to use low level laser therapy for general improvement of hospitalized COVID-19 patients in intensive care units by decreasing the length of hospitalization of these patients through improving ventilation and immune response, and decreasing inflammation.

Previous work done by Leal-Junior and his team at the Laboratory of Phototherapy and Innovative Technology (LaPIT) on human performance enhancement with light sparked interest in the researchers at the Hospital Tacchini located in Bento Gonçalves – RS (Brazil).

“Prior trials have successfully demonstrated improvement in lung function in chronic obstructive pulmonary disease (COPD) patients. The hospital contacted us due to the solid and robust outcomes published in many randomized clinical trials using Multi Radiance technology,” says Leal-Junior.

Multi Radiance has over 30 peer-reviewed, published studies validating its technology as safe and effective for pain relief and accelerated recovery. The company has a history of innovation, participating in trials and securing patents in fibromyalgia, neurology, ophthalmology, and now immunology with this new clinical trial.

“This pandemic has impacted us all greatly. Multi Radiance is excited to partake in a trial that could become a piece of the critical care solution for COVID-19 patients,” says Founder and CEO Max Kanarsky.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”